Morphological assessment of changes in internal organs of rats with introduction of targeted drug “Sutent” in experiment
- Authors: Gulyaeva N.I.1, Vdovina G.P.1, Freind G.G.1, Burlutskaya A.A.1, Chugunova M.P.1, Karipova M.O.1
-
Affiliations:
- E.A. Vagner Perm State Medical University
- Issue: Vol 40, No 1 (2023)
- Pages: 151-163
- Section: Biology and experimental medicine
- URL: https://journals.rcsi.science/PMJ/article/view/144140
- DOI: https://doi.org/10.17816/pmj401151-163
- ID: 144140
Cite item
Full Text
Abstract
Objective. To establish in the experiment the changes in histological structure of the internal organs and blood indices in laboratory rats with intragastric introduction of the drug Sutent® in the doses of 7 mg/kg and 35 mg/kg of the weight.
Materials and methods. The study was conducted on 48 breedless white rats divided into the following groups: groups 1 and 4 – received cytotoxic drug Sutent® in the dose of 7 mg/kg (therapeutic dose), groups 2 and 5 – Sutent® in the dose of 35 mg/kg (fivefold exceeding the therapeutic dose), groups 3 and 6 – the control groups. In groups 1, 2, 3 animal were killed 30 days after the onset of the experiment, in groups 4, 5, 6 – two weeks after the drug withdrawal. Every day during 30 days, the experimental groups were introduced the intragastric drug Sutent® in the form of aqueous suspension in the purified water; in the control group the rats received the purified water in the equivalent volume. The histological preparations of organs stained with hematoxylin and eosin as well as the hematological indices of blood were investigated.
Results. The development of hypochromic anemia, thrombocytopenia and granulocytopenia in the was identified. While studying the histological structure of organs, in all experimental groups there was detected a disturbed circulation in the form of venous hyperemia and blood stasis in the capillaries, the development hemorrhages in the lung, liver, kidneys, adrenal glands, pancreas, gastric and esophageal mucosa. In the liver, pancreas and adrenal glands, dystrophic changes in the cells and necrosis foci were observed. In group 2, affection of the cerebral cortex nerve cells, heart cardiomyocytes, thyroid cells, acute duodenitis with formation of microabscesses was established.
Conclusions. Introduction of Sutent® in the dose of 35 mg/kg, compared with the dose of 7 mg/kg, caused a more expressed hematological, hepatological, cardiological and neurological toxicity, more obvious lesion of endocrine organs; it also contributed to the development of associated secondary infection and acute duodenitis.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Natalya I. Gulyaeva
E.A. Vagner Perm State Medical University
Author for correspondence.
Email: bizon55@mail.ru
ORCID iD: 0000-0003-0572-7594
Scopus Author ID: 598754
https://e.mail.ru/inbox/
Candidate of Medical Sciences, leading researcher of the Central Scientific Research Laboratory
Russian Federation, PermG. P. Vdovina
E.A. Vagner Perm State Medical University
Email: bizon55@mail.ru
Doctor of Pharmaceutical Sciences, Professor, Head of the Department of Pharmacology
Russian Federation, PermG. G. Freind
E.A. Vagner Perm State Medical University
Email: bizon55@mail.ru
MD, PhD, Professor, Head of the Department of Pathological Anatomy with Sectional Course
Russian Federation, PermA. A. Burlutskaya
E.A. Vagner Perm State Medical University
Email: bizon55@mail.ru
Lecturer of the Department of Pharmacology
Russian Federation, PermM. P. Chugunova
E.A. Vagner Perm State Medical University
Email: bizon55@mail.ru
Candidate of Pharmaceutical Sciences, leading researcher of the Central Scientific Research Laboratory
Russian Federation, PermM. O. Karipova
E.A. Vagner Perm State Medical University
Email: bizon55@mail.ru
Assistant of the Department of Microbiology and Virology
Russian Federation, PermReferences
- Blinov V.S., Blinova A.S., Petkau V.V., Demidov S.M. Criteria for responses of kidney cancer metastases to targeted and immunotherapy. J. Radiol. Nuclear Med. 2020; 101 (4): 206–213 (in Russian).
- Yolla Haibe, Malek Kreidieh, Hiba El Hajj, Ibrahim Khalifeh, Deborah Mukherji, Sally Temraz, Ali Shamseddine. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front Oncol. 2020; 27 (10): 221.
- Alekseev B.YA., Kalpinskij A.S., Muhomed'yarova A.A., Nyushko K.M., Kaprin A.D. Targeted therapy of patients with metastatic kidney cancer with an unfavorable prognosis. Oncourology 2017; 13 (2): 49–55 (in Russian).
- La Vine, D.B. T., Coleman T.A., Davis C.H., Carbonell C.E., Davis W.B. Frequent Dose Interruptions are Required for Patients Receiving Oral Kinase Inhibitor Therapy for Advanced Renal Cell Carcinoma. Am. J. Clinic. Oncology 2010; 33 (3): 217–220.
- Alekseev B.YA., Kaprin A.D., Kolesnikov G.P., Muhomed'yarova A.A., Konopleva E.I., Kalpinskij A.S. Modern possibilities of treatment of metastatic renal cell carcinoma. Oncourology 2018; 14 (3): 25–35 (in Russian).
- Mashchelueva A.YU., Abramov M.E. Modern aspects of the use of Sutent in oncological practice. Effective pharmacotherapy 201; 3: 52–54 (in Russian).
- Alekseev B.YA. Metastatic kidney cancer: the choice of first-line therapy. Oncourology 2014; 3: 43–48 (in Russian).
- Guidelines for the experimental (preclinical) study of new pharmacological substances. Edited by R.U. Khabrieva. Moscow: JSC "Publishing House "Medicine" 2005; 832 (in Russian).
- Gutorov S.L., Borisova E.I. Practical recommendations for the prevention and correction of side effects of sunitinib. Oncourology 2010; 2: 8–13 (in Russian).
- Wenjing Luo, Chenggong Li, Yinqiang Zhang, Mengyi Du, Haiming Kou, Cong Lu, Heng Mei, Yu Hu. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.BMC. Cancer 2022; 22 (1): 98.
- Alekseev B.YA., Kalpinskij A.S. Targeted therapy of advanced kidney cancer with Sutent: side effects and their correction. Oncourology 2008; 3: 31–38 (in Russian).
- Hvastunov R.A., Skrypnikova G.V., Usachev A.A. Targeted therapy in oncology. Medicinal Bulletin 2014; 4 (56): 3–10 (in Russian).
- Fatema Tuz Zahra, Sanaullah Sajib, Constantinos M. Mikelis. Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer. Cancers (Basel) 2021; 13 (6): 1422.
- Shaheen R.M., Tseng W.W., Davis D.W., Liu W., Reinmuth N., Vellagas R., Wieczorek A.A., Ogura Y., McConkey D.J., Drazan K.E., Bucana C.D., McMahon G., EllisL.M. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 2001; 61 (4): 1464–1468.
- Terada T., Noda S., Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015; 152: 125–134.
- Dorohina E.I. Long-term results and toxicity of high-dose chemotherapy in adult patients with diffuse B-large cell lymphoma according to the modified NHL-BFM-90 program: avtoref. dis. … kand. med. nauk. Moscow 2016; 26 (in Russian).
- Du Souich P., Fradette C. The effect and clinical consequences of hepoxia on cytochrome P450, membrane carrier proteins activity and expression. Expert Opion Drug Metab. Toxicol. 2011; 7 (9): 1083–1100.
- Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., Woulfe K., Pravda E., Cassiola F., Desai J., George S., Morgan J.A., Harris D.M., Ismail N.S., Chen J.H., Schoen F.J., Van den Abbeele A.D., Demetri G.D., Force T., Chen M.H.Cl. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–2019.
- Wu M.D., Moslehi J.J., Lindner J.R. Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors. Arterioscler. Thromb. Vasc. Biol. 2021; 41 (1): 3–10.
- Duchnowska R., Loibl S., Jassem J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat. Rev. 2018; 67: 71–77.
- HutsonT.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. Оncologist 2008; 13 (10): 1084–1096.
- Rini B.I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., Reddy S., Dreicer R., Bukowski R.M. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer. Inst. 2007; 99 (1): 81–83.
- Sikic D., Ludecke G., Lieb V., Keck B. Side effect management of tyrosine kinase inhibitors in urology: Fatigue and hypothyroidism. Urologe A. 2016; 55 (5): 648–652 (in German).
- Alekseev B.Ya., SHegaj P.V. Targeted therapy of advanced kidney cancer. Oncourology 2007; 4: 6–11 (in Russian).
- Toropova I. Yu. Clinical monitoring of infectious complications in patients with hemoblastosis on the background of program chemotherapy: avtoref. dis. … kand. med. nauk. Moscow 2015; 24 (in Russian).
- Sakaeva D.D., Orlova R.V., SHabaeva M.M. Practical recommendations for the treatment of infectious complications of febrile neutropenia and the appointment of colony-stimulating factors in cancer patients. Russian Society of Clinical Oncology 2019; 9 (3s2): 585–594 (in Russian).
- Gazzaniga G., Villa F., Tosi F., Pizzutilo E.G., Colla S., D’Onghia S, Di Sanza G., Fornasier G., Gringeri M., Lucatelli M.V., Mosini G., Pani A., Siena S., Scaglione F., Sartore-Bianchi A. Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review. Cancers 2022; 14: 1666.
